ANTX- An2 Therapeutics, Inc.

Name: An2 Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

An2 Therapeutics, Inc. (ANTX) has 15 insiders with recent SEC Form 4 filings, including 2 buys and 15 sells. ANTX is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Leonard Braden Michael	3.22M	$14.83M	-
Other	Eizen Joshua M	92.0K	$423.2K	-
Dir	Marks Gilbert Lynn	79.1K	$363.8K	-
CFO	Day Lucy	73.7K	$338.9K	-
Other	Williams Sarah Joanne	67.2K	$309.0K	-

Activity

Buys and sells only

Transactions

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 6, 2026	Chanda Sanjay55	Chief Development Officer	Sell	9,251	$1.01	$9,332.36	-5.5%	+215.0%	-
Jan 6, 2026	Day Lucy55	Chief Financial Officer	Sell	8,807	$1.01	$8,883.03	-5.3%	+215.0%	-
Jan 6, 2026	Eizen Joshua M60	See Remarks	Sell	24,854	$1.00	$24,962.26	-7.4%	+215.0%	-
Jan 6, 2026	Prior Stephen David60	Chief Strategy Officer	Sell	6,462	$1.01	$6,507.11	-5.1%	+215.0%	-
Nov 4, 2025	Prior Stephen David60	Chief Strategy Officer	Sell	765	$1.14	$872.10	-1.2%	-1.8%	-
Nov 4, 2025	Eizen Joshua M60	See Remarks	Sell	2,819	$1.14	$3,213.66	-1.6%	-1.8%	-
Jun 2, 2025	Easom Eric74	Chief Executive Officer	Buy	10,000	$1.07	$10,665.00	+4.1%	+8.5%	-
May 30, 2025	Leonard Braden Michael61	10% Owner	Sell	2,532,000	$1.13	$2,872,476.80	-15.5%	+3.8%	-
May 28, 2025	Leonard Braden Michael61	10% Owner	Sell	200,000	$1.09	$218,000.00	-6.2%	0.0%	-
May 28, 2025	Fitzpatrick Margaret M	Director	Buy	8,610	$1.18	$10,133.11	New	0.0%	-

Page 1Next →

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC